Established risk factors for venous thromboembolism (VTE) include: Obesity (BMI 30 kg/m), which increases venous stasis and pro-inflammatory states Immobility or reduced mobility , particularly relevant in patients with severe obesity Previous history of VTE or family history of thrombophilia Active malignancy or recent surgery Hormonal therapies , including combined oral contraceptives or hormone replacement therapy Pregnancy and the postpartum period Smoking , which affects endothelial function and coagulation Risk factors for arterial thrombosis (myocardial infarction, stroke) include: Type 2 diabetes mellitus , associated with endothelial dysfunction, platelet hyperreactivity, and a prothrombotic state Hypertension , causing arterial wall damage Dyslipidaemia , promoting atherosclerotic plaque formation Established cardiovascular disease Chronic kidney disease , common in diabetes and associated with increased cardiovascular risk Patients initiating GLP-1 therapy should undergo a comprehensive cardiovascular risk assessment
With more than 15 years serving Scottsdale and the Phoenix metro, our practice is trusted for safe, natural-looking results and a philosophy that prioritizes health and confidence over quick fixes
The PlexusDx Precision Peptide Genetic Test identifies key variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)genes that directly influence how your body processes and responds to GLP-1 therapy
The level of pancreatic cholesterol in the T2DM and T2DM + sham group was markedly higher than the NC group, while compared to the T2DM + sham group, pancreatic cholesterol level dramatically decreased in T2DM + RYGB and T2DM + EX-4 groups (Figure 6J)
What if I inject my GLP-1 incorrectly
In the ventral hippocampus, we found no significant main effects or interactions (all p 0.334
